Trial Profile
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers in Young Girls.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Genital warts; Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- 06 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2013 to 1 Jun 2014.
- 07 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.